A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Celgene
Takara Bio Inc.
Astellas Pharma Inc
Delta-Fly Pharma, Inc.
Astellas Pharma Inc
Gilead Sciences
Gilead Sciences
Sunshine Lake Pharma Co., Ltd.
Hoffmann-La Roche
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Cornerstone Pharmaceuticals
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CTI BioPharma
Hoffmann-La Roche
Pfizer
Pfizer
US Oncology Research